AlphaCentric Advisors’s Sanofi SNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$633K Buy
15,345
+755
+5% +$32.8K 0.56% 53
2026
Q2
$622K Buy
14,590
+208
+1% +$9.29K 0.53% 65
2026
Q1
$693K Buy
14,382
+788
+6% +$36.7K 0.69% 37
2025
Q4
$659K Buy
+13,594
New +$674K 0.66% 43
2024
Q4
– Sell
-17,500
Closed -$1.01M – 276
2024
Q3
$1.01M Hold
17,500
– – 0.75% 46
2024
Q2
$849K Buy
17,500
+2,500
+17% +$121K 0.63% 57
2024
Q1
$729K Buy
+15,000
New +$732K 0.44% 74
2023
Q2
– Sell
-10,000
Closed -$544K – 272
2023
Q1
$544K Sell
10,000
-10,000
-50% -$486K 0.38% 82
2022
Q4
$969K Sell
20,000
-35,500
-64% -$1.56M 0.96% 37
2022
Q3
$2.11M Buy
+55,500
New +$2.47M 2.17% 4
2021
Q4
$301K Buy
+6,000
New +$297K 0.09% 82

Other funds holding SNY

AlphaCentric Advisors's SNY Position: Q3 2026 in Review

AlphaCentric Advisors increased its Sanofi (SNY) stake by 5.2% in Q3 2026, buying an estimated $32.8K and bringing the position to 15,345 shares worth $633K. The position accounts for 0.56% of the portfolio, ranked #53.

AlphaCentric Advisors first reported a position in SNY in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.11M in Q3 2022. 687 funds tracked by Wall St. Rank hold SNY as of Q3 2026.

  • AlphaCentric Advisors held 15,345 shares of Sanofi worth $633K as of Q3 2026.
  • AlphaCentric Advisors bought 755 Sanofi shares in Q3 2026, an estimated $32.8K.
  • Sanofi made up 0.56% of AlphaCentric Advisors's portfolio in Q3 2026, its #53 holding.
  • AlphaCentric Advisors first reported a position in Sanofi in Q4 2021 and has held it in 11 quarters since.
  • AlphaCentric Advisors's Sanofi position peaked at $2.11M in Q3 2022.
  • 687 funds tracked by Wall St. Rank held Sanofi as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.